Indication
In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

Medicine details

Medicine name:
venetoclax (Venclyxto)
SMC ID:
SMC2166
Pharmaceutical company
AbbVie Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
06 May 2019